Concerning sensitivity, no major improvement is observed when both biomarkers are used together, as seven out of eight patients (87.5%) who developed HCC presented levels above 5 ng/mL of AFP and >29 UI/L of ALT. The gene discussed is AFP; the disease is hepatocellular carcinoma.